Search
GDC-0927
go.drugbank.com/drugs/DB14934InvestigationalGDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer).
Tigatuzumab
go.drugbank.com/drugs/DB15101InvestigationalTigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).
Rasdegafusp alfa
go.drugbank.com/drugs/DB15185InvestigationalRasdegafusp alfa is under investigation in clinical trial NCT03206047 (Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal
PR1 leukemia peptide vaccine
go.drugbank.com/drugs/DB15276InvestigationalPR1 leukemia peptide vaccine is under investigation in clinical trial NCT00513578 (Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome).
Cardiopet
go.drugbank.com/drugs/DB18913InvestigationalCardiopet is under investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects).
Rostaporfin
go.drugbank.com/drugs/DB06659InvestigationalCategories: Heterocyclic Compounds with 4 or More RingsVirginiamycin M1
go.drugbank.com/drugs/DB01669ExperimentalPristinamycin IIA is a macrolide antibiotic, a member of the streptogramin A group of antibiotics, and one component of pristinamycin. It is produced by Streptomyces graminofaciens and other bacteria.
Silmitasertib
go.drugbank.com/drugs/DB15408InvestigationalSilmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).
Cinitapride
go.drugbank.com/drugs/DB08810InvestigationalCinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.
Categories: Drugs for Functional Gastrointestinal Disorders